Bharat Biotech International
Chairman & Managing Director: Dr Krishna Ella
Total Revenue: Rs 450 crore
Bharat Biotech International (Bharat Biotech) is an innovation leader and a multi-dimensional biotechnology company, specializing in product-oriented research and development, manufacturing and marketing of vaccines and biotherapeutics.
In a short span of less than 20 years, the company has 20 products in the market and about 50 patents showcasing innovation and dedication of the team.
Bharat Biotech clocked revenue of Rs 450 crore in the FY 15-16, against Rs 322.24 crore in the FY 14-15. Domestic sales contributed majority of the revenue with Rs 278.25 crore and exports contributed Rs 171.75 crore.
The company's inline portfolio contains vaccines for Hepatitis B (Revac-B), Hemophilus influenza (BioHib), Polio (BIOPOLIO), Pertussis, Tetanus (Comvac4-HB, Comvac5, Comvac3) Rabies (INDIRAB), Japanese encephalitis (JENVAC), Rotavirus (ROTAVAC) and typhoid fever (TypbarTCV). The biotherapeutic line of products comprises of BIOGIT, REGEN-D, SLVRGEN and ZELECT.
The firm had quite an eventful year in the previous fiscal. Some of the major activities include launch of rotavirus vaccine, ROTAVAC in Indian markets in April 2015; announcement of ZIKAVAC - first vaccine candidate against Zika virus in February 2016.
In March 2016, rotavirus vaccine was launched as part of the Universal Immunization Program.